Рroblems and ways to correct anticoagulant therapy in patients with coronavirus infection

Musaeva L.J, Yakubov A.V, Akbarova D.S, Yuldasheva D.K.

dc.contributor.author	Musaeva L.J, Yakubov A.V, Akbarova D.S, Yuldasheva D.K.
dc.date.accessioned	2022-10-07T05:23:48Z
dc.date.available	2022-10-07T05:23:48Z
dc.date.issued	2022
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/2508
dc.description.abstract	Patients with COVID 19 have a hypercoagulable state, which increases the risk of thrombosis and thromboembolic complications. This condition is also called COVID 19 associated coagulopathy, which manifests as increased fibrinogen and D-dimer levels, prolongation of aPTT (Activated Partial Thromboplastin Time) and PT (Prothrombin time), changes in platelet levels in the early stage of the disease. This article discusses issues and problems of rational anticoagulant therapy in patients with coronavirus infection	en_US
dc.language.iso	en	en_US
dc.publisher	Анапа	en_US
dc.relation.ispartofseries	УДК;616
dc.subject	COVID 19 associated coagulopathy, anticoagulant therapy, hepa rin, low molecular weight heparins, D- dimer	en_US
dc.title	Рroblems and ways to correct anticoagulant therapy in patients with coronavirus infection	en_US
dc.type	Article	en_US